A deep learning platform to assess drug proarrhythmia risk-Reference-Cited by-同舟云学术

A deep learning platform to assess drug proarrhythmia risk

Published:2023-01 Issue:1 Volume:30 Page:86-95.e4
ISSN:1934-5909
Container-title:Cell Stem Cell
language:en
Short-container-title:Cell Stem Cell

Author:

Serrano Ricardo,Feyen Dries A.M.,Bruyneel Arne A.N.,Hnatiuk Anna P.,Vu Michelle M.,Amatya Prashila L.,Perea-Gil Isaac,Prado Maricela,Seeger Timon,Wu Joseph C.,Karakikes Ioannis,Mercola Mark^ORCID

Publisher

Elsevier BV

Subject

Cell Biology,Genetics,Molecular Medicine

Reference60 articles.

1. Developing solutions to detect and avoid cardiovascular toxicity in the clinic;Valentin;Toxicology Letters,2018

2. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature;Onakpoya;BMC Med.,2016

3. An analysis of the attrition of drug candidates from four major pharmaceutical companies;Waring;Nat. Rev. Drug Discov.,2015

4. Cardiac dysrhythmias associated with the intravenous administration of ondansetron and metoclopramide;Baguley;Anesth. Analg.,1997

5. Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms;Frommeyer;Nat. Rev. Cardiol.,2016

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. AI‐organoid integrated systems for biomedical studies and applications;Bioengineering & Translational Medicine;2024-01-20

2. Harnessing human genetics and stem cells for precision cardiovascular medicine;Cell Genomics;2023-11

3. Intelligence artificielle et rythmologie : apports et limites;Archives des Maladies du Coeur et des Vaisseaux - Pratique;2023-03